Application of rhinoceros horn and rehmannia glutinosa composition in preparation of medicine for preventing and treating related rash caused by epidermal growth factor receptor inhibitor

Abstract

The invention provides application of a rhinoceros horn and rehmannia glutinosa composition in preparation of a medicine for preventing and treating related rash caused by an epidermal growth factor receptor inhibitor. The rhinoceros horn and rehmannia glutinosa composition includes rhinoceros horns, radix paeoniae rubra, radix rehmanniae and cortex moutan serving as effective ingredients. The medicine composition prepared by rhinoceros horn and rehmannia glutinosa decoction for treating severe hepatitis, hepatic coma, uremia, allergic purpura, acute leukemia, sepsis syndrome and other symptoms is creatively used for preventing and treating the rash caused by the epidermal growth factor receptor inhibitor, is better in clinical curative effect and low in toxicity and can be taken for a long time.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to a new application of a rhino horn rehmannia medicinal composition, in particular to the application of the rhino horn rehmannia medicinal composition in the preparation of drugs for preventing and treating skin rashes caused by epidermal growth factor receptor inhibitors. Background technique [0002] With the development of society and technology, the concept of cancer treatment has changed from empirical science to evidence-based medicine, from cell attack mode to targeted treatment mode. "Target therapy" controlled by tumor-specific signal transduction or specific metabolic pathway is a hot spot in tumor research. [0003] Targeted drugs refer to anti-tumor drugs that target the identified oncogenic driver genes. Its purpose is to enable the drug or its carrier to target a specific driver gene, so that tumor cells can die specifically without affecting normal cells in the human body. T...

AI Technical Summary

Problems solved by technology

[0004] However, the current anti-tumor targeted drugs inevitably have various side effects, especially skin rash and mucositis caused by targeted drugs.

These side effects of skin lesions seriously affect the quality of life of cancer patients

Moreover, patients with grade III and IV toxicity accounted for 1 / 3. Such patients were forced to reduce the dose of targeted drugs or even stop the drug, which affected the treatment effect and led to tumor recurrence and metastasis.

[0005] At present, the drugs commonly used in clinic to treat or relieve the above-mentioned skin lesions include moisturizers, topical hormone drugs, and oral minocycline. damage

Therefore, there is no good clinical treatment for rashes caused by targeted drugs, especially epidermal growth factor inhibitors.